Millendo Therapeutics

Developing novel, disease-modifying treatments for orphan endocrine diseases

Millendo Therapeutics (formerly Atterocor) is developing a portfolio of treatments for orphan endocrine disorders with limited or no approved treatment options. The company’s clinical-stage pipeline includes livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome.

Status
Reverse Merger in 2018 (NASDAQ: MLND)
Year of Investment
2012
Strategy
Life Sciences
Location
Ann Arbor, Michigan